Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
作者信息
Flanders Aaron, Stetler-Stevenson Maryalice, Landgren Ola
出版信息
Blood. 2013 Aug 8;122(6):1088-9. doi: 10.1182/blood-2013-05-506170.
Abstract
摘要
相似文献
1
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.采用流式细胞术检测多发性骨髓瘤微小残留病：存在显著异质性。
Blood. 2013 Aug 8;122(6):1088-9. doi: 10.1182/blood-2013-05-506170.
2
Clinician attitudes and practices toward measurable residual disease in multiple myeloma.临床医生对多发性骨髓瘤中可测量残留病的态度和实践。
Br J Haematol. 2020 Aug;190(3):470-472. doi: 10.1111/bjh.16805. Epub 2020 Jun 7.
3
Minimal residual disease in multiple myeloma: why, when, where.多发性骨髓瘤的微小残留病：为何、何时、何地。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):37-45. doi: 10.1182/hematology.2021000230.
4
Multiple myeloma: disease response assessment.多发性骨髓瘤：疾病缓解评估。
Expert Rev Hematol. 2016 Sep;9(9):831-7. doi: 10.1080/17474086.2016.1212654. Epub 2016 Jul 25.
5
A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.一种用于检测骨髓瘤微小残留病的单管六色流式细胞术筛查检测方法。
Leukemia. 2007 Sep;21(9):2046-9. doi: 10.1038/sj.leu.2404815. Epub 2007 Jul 26.
6
MRD Assessment in Multiple Myeloma: Progress and Challenges.多发性骨髓瘤中的微小残留病灶评估：进展与挑战。
Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5.
7
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.4种血液淋巴系统肿瘤报告的微小残留病检测下限存在显著差异：美国病理学家学会流式细胞术能力验证计划参与者调查
Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP. Epub 2015 Feb 19.
8
An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.多参数流式细胞术检测多发性骨髓瘤微小残留病的假阴性率分析
Int J Lab Hematol. 2020 Apr;42(2):e65-e67. doi: 10.1111/ijlh.13112. Epub 2019 Sep 20.
9
Measurable Residual Disease and Decision-Making in Multiple Myeloma.多发性骨髓瘤的可测量残留疾病与决策。
Hematol Oncol Clin North Am. 2024 Apr;38(2):477-495. doi: 10.1016/j.hoc.2023.12.009. Epub 2024 Jan 6.
10
Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.用于评估多发性骨髓瘤患者血液、骨髓和单采细胞中微小残留病的标准化检测方法。
Sci Rep. 2019 Feb 27;9(1):2922. doi: 10.1038/s41598-019-39631-2.
引用本文的文献
1
Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications.单细胞分析对多发性骨髓瘤的见解：克隆进化、微环境、治疗逃逸及临床意义
Cancers (Basel). 2025 Feb 14;17(4):653. doi: 10.3390/cancers17040653.
2
Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.金纳米材料在血液系统恶性肿瘤中的诊疗潜力
Cancers (Basel). 2022 Jun 21;14(13):3047. doi: 10.3390/cancers14133047.
3
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.采用高敏流式细胞术评估多发性骨髓瘤可测量残留病灶：数据分析的国际协调方法。
Cytometry B Clin Cytom. 2022 Mar;102(2):88-106. doi: 10.1002/cyto.b.22053. Epub 2022 Jan 10.
4
Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium.波兰骨髓瘤联盟各中心多发性骨髓瘤流式细胞术微小残留病评估的标准化
Diagnostics (Basel). 2021 Oct 11;11(10):1872. doi: 10.3390/diagnostics11101872.
5
Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.国际临床试验中流式细胞术微小残留病评估的标准化——来自欧洲骨髓瘤网络的一项可行性研究
Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831.
6
Discovery and validation of surface -glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets.在 MM 细胞系和患者样本中发现和验证表面糖蛋白，可揭示免疫治疗靶点。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000915.
7
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.定义不可检测：多发性骨髓瘤中微小残留病评估的现状和未来明确目标。
Blood Rev. 2021 Mar;46:100732. doi: 10.1016/j.blre.2020.100732. Epub 2020 Jul 10.
8
Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.采用新一代流式细胞术对硬化性黏液水肿患者循环骨髓瘤肿瘤细胞进行表征：一例报告
Medicine (Baltimore). 2020 Jul 2;99(27):e20726. doi: 10.1097/MD.0000000000020726.
9
Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.多发性骨髓瘤可测量残留病灶检测的临床价值及其在日本的应用。
Int J Hematol. 2020 Apr;111(4):519-529. doi: 10.1007/s12185-020-02828-7. Epub 2020 Feb 7.
10
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.微小残留病阴性和来那度胺维持治疗与多发性骨髓瘤的更好生存结果相关。
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
本文引用的文献
1
Treating myeloma: the future is already here!治疗骨髓瘤：未来已来！
Blood. 2012 Aug 30;120(9):1754-6. doi: 10.1182/blood-2012-06-434571.
2
Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.正常浆细胞免疫表型异质性：与微小残留浆细胞骨髓瘤的比较。
J Clin Pathol. 2012 Sep;65(9):823-9. doi: 10.1136/jclinpath-2012-200881. Epub 2012 Jun 8.
3
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.免疫固定电泳、血清游离轻链与免疫表型分析在多发性骨髓瘤中的疗效评估和预后判断中的比较。
J Clin Oncol. 2011 Apr 20;29(12):1627-33. doi: 10.1200/JCO.2010.33.1967. Epub 2011 Mar 14.
4
Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.流式细胞术多参数免疫表型分析在多发性骨髓瘤中的应用：与组织学相比，定义正常抗原表达范围的诊断效用。
Cytometry B Clin Cytom. 2010 Jul;78(4):231-8. doi: 10.1002/cyto.b.20517.
5
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.欧洲骨髓瘤网络关于多发性骨髓瘤及相关疾病的多参数流式细胞术报告。
Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11.
Zotero 插件